Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application

Ghatnekar, Ola; Hjalte, Frida; Taylor, Matthew

doi:10.3109/0284186x.2010.495132

Cited by 30 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, second-line dasatinib was excluded from the recommendation by NICE. Further analyses evaluating dasatinib or nilotinib are published by Ghatnekar et al [51] and Hoyle et al [52]. However, these analyses only evaluate the second-line use of the second-generation TKIs.…”

Section: J U S T a C C E P T E Dmentioning

confidence: 97%

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

Rochau¹,

Sroczynski²,

Wolf

et al. 2015

Leukemia & Lymphoma

View full text Add to dashboard Cite

Several tyrosine kinase inhibitors (TKIs) are approved for chronic myeloid leukemia (CML) therapy. We evaluated the long-term cost-effectiveness of seven sequential therapy regimens for CML in Austria. A cost-effectiveness analysis was performed using a state-transition Markov model. As model parameters, we used published trial data, clinical, epidemiological and economic data from the Austrian CML registry and national databases. We performed a cohort simulation over a life-long time-horizon from a societal perspective. Nilotinib without second-line TKI yielded an incremental cost-utility ratio of 121,400 €/quality-adjusted life year (QALY) compared to imatinib without second-line TKI after imatinib failure. Imatinib followed by nilotinib after failure resulted in 131,100 €/QALY compared to nilotinib without second-line TKI. Nilotinib followed by dasatinib yielded 152,400 €/QALY compared to imatinib followed by nilotinib after failure. Remaining strategies were dominated. The sequential application of TKIs is standard-of-care, and thus, our analysis points toward imatinib followed by nilotinib as the most cost-effective strategy.

show abstract

Section: J U S T a C C E P T E Dmentioning

confidence: 97%

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

Rochau¹,

Sroczynski²,

Wolf

et al. 2015

Leukemia & Lymphoma

View full text Add to dashboard Cite

show abstract

“…Given that all currently available long-term data, as well as clinical opinion, were used to construct the model, validation of these results is complex and largely indirect. However, BMS compared the results from this model with those from other models (Reed et al, 116 (AiC information has been removed), PenTAG 2009, Ghatnekar et al 175 ), and with additional short-term clinical data not used in model construction. 144,182 Uncertainty has been characterised through the use of statistical distributions.…”

Section: Model Validationmentioning

confidence: 99%

“…This relationship has been demonstrated in the clinical literature and used in a recently published model of interventions for imatinib resistant CML patients. 104,[173][174][175] The data for the OS curve and PFS curves are taken from a number of different sources. Table 64 summarises the sources used.…”

Section: Survival Estimatesmentioning

confidence: 99%

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Pavey

Hoyle²,

Ciani³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTADasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills ...

show abstract

“…Dasatinib has been assessed as good value for money versus high-dose imatinib for people resistant to standard dose imatinib in the Swedish healthcare system, according to a study with financial support from BMS [10]. Based on a societal perspective, the incremental cost is €6880 (in Euros) per QALY, and allowing for direct costs only, €7207 per QALY (approximately £6000 [pound sterling] per QALY).…”

Section: Discussionmentioning

confidence: 99%

“…Bristol-Myers Squibb (BMS), the manufacturer of dasatinib, and Novartis, the manufacturer of nilotinib, recently made submissions to the National Institute of Health and Clinical Excellence (NICE), which included cost-effectiveness analyses for dasatinib and nilotinib [3]. In addition, dasatinib has recently been assessed as a good value for money compared with high-dose imatinib for patients resistant to standard dose imatinib in Sweden, according to a study with financial support from BMS [10]. The decision analytic model, and subsequent cost-effectiveness analysis, presented here formed part of the independent assessment report submitted to NICE (by the authors) and were used to inform the NICE Health Technology Appraisal process [3].…”

Section: Introductionmentioning

confidence: 99%

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

et al. 2011

View full text Add to dashboard Cite

The model should be viewed as an exploratory analysis of the cost-effectiveness of dasatinib and nilotinib because it relies on many assumptions. Whilst clinical data remains immature, the cost-effectiveness of dasatinib and nilotinib for imatinib-resistant people is highly uncertain. Both nilotinib and dasatinib are highly unlikely to be cost-effective versus interferon-α for people intolerant to imatinib.

show abstract

Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application

Abstract: The results indicate that dasatinib is a cost-effective treatment among imatinib-resistant CML patients in Sweden in comparison to imatinib 800 mg/daily.

Cited by 30 publications

References 16 publications

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Contact Info

Product

Resources

About